Drugs potentially affecting the extent of airways reversibility on pulmonary function testing are frequently consumed despite guidelines

Terry E Jones¹
AnneMarie Southcott²
Sean Homan³
¹Pharmacy Department, The Queen Elizabeth Hospital, Woodville South, SA, ²Respiratory and Sleep Medicine, Western Health, Footscray, VIC, ³Respiratory Unit, The Queen Elizabeth Hospital, Woodville South, SA, Australia

Background: The increase in forced expiratory volume in one second (FEV₁) effected by a bronchodilator is routinely assessed when patients undertake pulmonary function testing (PFT). Several drug classes can theoretically affect the magnitude of the increase in FEV₁. Withholding periods are advised for many but not all such drugs. Anecdotally, many subjects presenting for PFT are found to have taken drugs that might affect the test. We did an audit of patients presenting for PFT to assess the frequency with which FEV₁ reversibility might be affected by drugs.

Methods: One hundred subjects presenting to the laboratory for PFT were questioned about recent drug consumption by an independent pharmacy intern. Reversibility of FEV₁ was assumed to have been affected if drugs of interest were consumed within defined withholding periods or two half-lives for drugs without such data.

Results: Sixty-three subjects were prescribed drugs likely to affect FEV₁ reversibility. Thirty-six subjects consumed at least one such drug within the withholding period. Half (18) of these patients consumed β-blockers with or without β-agonists. Sixty-five subjects did not recall receiving any advice about withholding drugs prior to the test and only 10 recalled receiving advice from their clinician or pulmonary function technician.

Conclusion: Subjects presenting for PFT are infrequently advised to withhold drugs that may affect FEV₁ reversibility, and consequently, often take such drugs close to the time of the test. Therefore, it is likely that the increase in FEV₁ is frequently affected by interference from drugs and this might impact on diagnosis and/or treatment options.

Keywords: lung function tests, beta-adrenergic agonists, beta-adrenergic antagonists, withholding periods, bronchodilators

Introduction

Pulmonary function testing (PFT) usually includes an assessment of the forced expiratory volume in one second (FEV₁) before and after inhalation of a bronchodilator. The resulting increase in FEV₁ (ΔFEV₁) is valuable in both the diagnosis and management of reversible airways disease. Authoritative guidelines on how PFTs should be conducted have been published by a combined task force of the American Thoracic Society and the European Respiratory Society.¹ When the PFT is performed to demonstrate whether airflow reversibility is present, the guidelines recommend a baseline test be performed when the patient is “not taking any drugs prior to the test”. This advice is presumably given to reduce the likelihood that any of the metrics will be affected by prior drug use. Drugs likely to affect the caliber of the airways include beta-adrenergic agonists (β-agonists) and antagonists (β-blockers) and other bronchodilators.
The likelihood that any particular drug will affect any of the PFT metrics will depend on the number of molecules in the vicinity of the receptor at the time of the test, which is dependent upon the half-life of the drug. The guidelines recommend a four-hour withholding period for short-acting β-agonists (SABA) and ipratropium, and a 12-hour withholding period for long-acting β-agonists (LABA) and aminophylline/theophylline. There are no recommended withholding periods for the long-acting anticholinergic bronchodilator, tiotropium, ultralong-acting β-agonists (eg, indacaterol) or β-blockers.

Historically, it has been unlikely that patients taking β-blockers would have presented for PFT because these drugs were seen as relatively contraindicated in patients with airways disease. However, the magnitude of benefit afforded by β-blockers in heart failure and myocardial infarction is such that some advocate their use even when patients have reversible airways disease, although many advocate careful patient selection and/or PFT. While there are several studies on β-blocker use in patients with airways disease in the literature, they are typically limited by short duration of therapy, patient selection, or retrospective study design. A meta-analysis of 19 single-dose and 10 “continued treatment” (three days to four weeks) studies of cardioselective β-blocker use in patients with reactive airways disease concluded that these agents “…should not be withheld in patients with reactive airways disease or COPD.” The analysis revealed a decrease in FEV₁ of 7.5% in the single-dose studies (baseline FEV₁ 2.4 L) and of only 0.4% in the “continued treatment studies” (baseline FEV₁ 1.8 L). However, there were many limitations in the studies analyzed (noted by the authors), including methodological concerns, too few participants, and only moderate disease severity. In addition, the longest period of treatment was four weeks, which is too short to reliably capture events that might trigger airways reactivity, including upper respiratory tract infections and seasonal allergies.

Anecdotal evidence suggests that patients were presenting for PFT soon after consuming drugs that might affect ΔFEV₁ and that, on occasion, a “negative” result (ie, one where the increase in FEV₁ was minimal) was interpreted as being safe to prescribe β-blockers. Therefore, we undertook an audit of 100 consecutive patients to assess the frequency with which drugs that might affect ΔFEV₁ were consumed within a defined withholding period.

Materials and methods

Patients presenting to our hospital pulmonary function laboratory, which is accredited by the Thoracic Society of Australia and New Zealand, were interviewed by a pharmacy intern either immediately prior to or after their planned PFT. Laboratory staff were only informed that a student counseling project was being conducted, so as to not affect usual practice of providing advice on withholding drugs of interest prior to PFT. Subjects were questioned about all usual practice consumed (prescribed, over-the-counter, cigarettes, alternative drugs), when they were taken, what advice was provided about withholding drugs prior to the PFT, and by whom the advice was provided.

Our laboratory practice is to perform a baseline FEV₁ and to repeat the test five minutes after inhaling four puffs of salbutamol 100 μg via a large-volume (750 mL) spacer. We assumed that the increase in FEV₁ would be affected by drugs if taken within the recommended withholding times (advised by the American Thoracic Society/European Respiratory Society guidelines). For tiotropium (no guidelines available), we adopted a 24-hour withholding period. For β-blockers, we adopted a withholding period equal to twice the reported half-life in normal subjects, ie, 12 hours for metoprolol and carvediol, 20 hours for atenolol, and 24 hours for bisoprolol and sotalol.

Results

One hundred “consecutive” patients (ie, convenience sampling) were interviewed. Fifty-one subjects were referred from respirologists and 10 from cardiologists. Twenty-six subjects were inpatients at the time of their PFT. Thirty-three subjects were taking drugs likely to affect PFT. Thirteen subjects were current smokers, four of whom had smoked within the recommended withholding period (one hour) prior to PFT.

Thirty-six subjects had taken at least one drug likely to affect ΔFEV₁ within the withholding period (Table 1). Of these, 18 were taking β-blockers (Table 2) and of these 18, six were also taking β-agonists (three combination inhaled corticosteroid/LABA, five SABA) and four were also prescribed anticholinergic bronchodilators. Because of the long half-life involved and the usual habit of taking drugs in the…

Table 1 Demographics for 100 patients audited regarding drugs consumed prior to pulmonary function testing

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number taking drugs every day</td>
<td>95</td>
</tr>
<tr>
<td>Number of patients taking potentially interfering drugs</td>
<td>63</td>
</tr>
<tr>
<td>Number of PFTs potentially affected by 1 drug</td>
<td>21</td>
</tr>
<tr>
<td>Number of PFTs potentially affected by 2 drugs</td>
<td>6</td>
</tr>
<tr>
<td>Number of PFTs potentially affected by 3 drugs</td>
<td>8</td>
</tr>
<tr>
<td>Number of PFTs potentially affected by 4 drugs</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviation: PFT, pulmonary function testing.
Drugs affecting pulmonary function testing

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Number used by patients</th>
<th>Number of tests affected</th>
<th>Number deliberately withheld</th>
</tr>
</thead>
<tbody>
<tr>
<td>SABA</td>
<td>47 (17 nebulizers)</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>LABA</td>
<td>31</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>18</td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td>β-blockers</td>
<td>18</td>
<td>17</td>
<td>1</td>
</tr>
</tbody>
</table>

Notes: PFTs were considered affected if the drug was taken within the withholding period or 2 x half-life value quoted in the product monograph. Drugs were considered deliberately withheld if advice was given to not take them prior to the test.

Abbreviations: PFT, pulmonary function testing; LABA, long-acting beta agonists; SABA, short-acting beta agonists.

Discussion

Almost two thirds of patients were prescribed at least one drug that might affect ∆FEV₁. Given the authoritative guidelines recommending withholding such drugs, we were surprised that almost 60% did not withhold them. Our accredited laboratory conducts more than 1000 PFTs annually and is typical of many public hospital PFT laboratories in Australia. Advice on withholding drugs was clearly suboptimal and warrants greater attention.

Of the 18 patients prescribed β-blockers, six were also prescribed bronchodilators (three LABA, five SABA, two tiotropium, and two ipratropium). Coprescription of β-blockers and β-agonists has been observed before, and while we did not investigate the reasons for the coprescription, this might be as a consequence of “compartmentalization” of respiratory and cardiac problems.5,8,10

Because we did not want to affect normal laboratory practice of providing advice on withholding drugs likely to affect ∆FEV₁, we were unable to repeat the PFT in the same laboratory on a proximate day when such drugs were withheld. Therefore we can only speculate about the effect on the magnitude of ∆FEV₁ caused by prior use of these drugs.

Superficially, it might be assumed that prior β-blocker consumption would lessen ∆FEV₁ (via competition with agonist salbutamol) while prior β-agonist consumption might enhance ∆FEV₁ (by increasing the number of agonist molecules). The potential effect is more complex and would depend on the numbers of agonist/antagonist molecules in the vicinity of the β-receptor, the numbers of β-receptors available, and the relative affinities of these molecules for the receptors. If salbutamol 400 µg maximally dilated the bronchioles, then post-bronchodilator FEV₁ could not be increased by prior β-agonist use, but baseline FEV₁ would likely be elevated (and hence ∆FEV₁ would be reduced). However, if salbutamol 400 µg was insufficient to dilate the bronchioles maximally, then prior β-agonist use might elevate both prebronchodilator and post-bronchodilator FEV₁, and if the magnitude of the effect on both was similar, ∆FEV₁ would be unaffected.

The effect of prior use of β-blockers would also depend upon the numbers of agonist and antagonist molecules (and their respective affinities) in the vicinity of β-receptors. If there were few endogenous agonist molecules present, baseline FEV₁ would likely not be affected by prior β-blocker use, and if salbutamol 400 µg produced just maximal or submaximal bronchodilatation, then β-blockers would likely reduce post-bronchodilator FEV₁. In this scenario, ∆FEV₁ would be reduced. However, if there were endogenous β-agonist molecules present, baseline FEV₁ would likely be reduced, and if the post-bronchodilator FEV₁ was similarly reduced, ∆FEV₁ might be unaffected. A final scenario would be if salbutamol 400 µg greatly exceeded the dose required for maximal bronchodilatation, then prior β-blocker use may not reduce post-bronchodilator FEV₁, and, unless baseline FEV₁ was reduced, ∆FEV₁ would be unaffected. This can be explained diagrammatically via “dose-response” curves (Figures 1–3) where the “effective dose” (horizontal axis) represents the net effect. This net effect consists of the sum of both endogenous and exogenous β-agonist molecules minus exogenous β-blocker antagonist molecules.

Published data suggest that salbutamol 400 µg is insufficient to produce maximal/supramaximal bronchodilatation and hence the scenarios in Figure 1B, Figure 2B, and Figure 3B are unlikely. In a study of 24 subjects with chronic obstructive pulmonary disease, the greatest relative increase in FEV₁ was achieved by increasing the salbutamol dose from...
Figure 1 Effect of prior β-agonist use on magnitude of FEV₁ increase (vertical arrows) if salbutamol 400 μg produces less-than-maximal bronchodilatation (A) or maximal bronchodilatation (B). Solid lines represent the situation (pre and post salbutamol 400 μg) that would have occurred without prior use of β-agonist and dotted lines represent the situation (pre and post salbutamol 400 μg) that would have occurred in the presence of the β-agonist. (A) Prior use of β-agonist moves the “effective dose” to the right (more agonist molecules present) but the response (magnitude of increase in FEV₁) is unaffected because the shift occurs on the linear portion of the curve. (B) Prior use of a β-agonist moves the “effective dose” to the right but the response (magnitude of increase in FEV₁) is greatly reduced because the shift occurs on the nonlinear portion of the curve.

Abbreviation: FEV₁, forced expiratory volume in one second.

Figure 2 Effect of prior use of β-blocker on magnitude of FEV₁ increase (vertical arrows) if salbutamol 400 μg produces just-maximal bronchodilatation (A) or is more than sufficient to produce maximal bronchodilatation (B) if baseline FEV₁ is unaffected by β-blocker. Solid lines represent the situation (pre and post salbutamol 400 μg) that would have occurred without prior use of β-blocker and dotted line represents the situation (post salbutamol 400 μg) that would have occurred in the presence of β-blocker. (A) Baseline FEV₁, unaffected by a β-blocker (no endogenous agonist molecules present) but the response (magnitude of increase in FEV₁) is greatly reduced due to competition for β-receptors by agonist and antagonist molecules (an effect equivalent to reducing the “effective dose”). (B) Baseline FEV₁ unaffected by the β-agonist, and the response (magnitude of increase in FEV₁) is unaffected because excess β-agonist molecules effectively compete for β-receptors and while the “effective dose” is reduced, the response remains maximal.

Abbreviation: FEV₁, forced expiratory volume in one second.

Figure 3 Effect of prior use of β-blockers on magnitude of FEV₁ increase (vertical arrows) if salbutamol 400 μg produces less than maximal bronchodilatation (A) or is more than sufficient to produce maximal bronchodilatation (B) if baseline FEV₁ is affected by prior β-blocker use. Solid lines represent the situation (pre and post salbutamol 400 μg) that would have occurred without prior use of β-blocker and dotted lines represent the situation (pre and post salbutamol 400 μg) that would have occurred in the presence of β-blocker. (A) Prior use of a β-agonist moves “effective dose” to the left (access to β-receptors by salbutamol is reduced) but the response (magnitude of increase in FEV₁) is unaffected because the shift is on the linear part of the curve. (B) Prior use of a β-agonist moves the “effective dose” to the left (access to β-receptors by salbutamol is reduced) but the response (magnitude of increase in FEV₁) is increased because excess β-agonist molecules effectively compete for β-receptors and while the “effective dose” is reduced, the response remains maximal. Whether the response would be an increase, no change or a decrease in response would depend upon the relative effects of the β-agonist on baseline and post-bronchodilator FEV₁ and where these values sit on the dose-response curve.

Abbreviation: FEV₁, forced expiratory volume in one second.
20 μg to 50 μg, but an increase in FEV₁ was observed over the entire salbutamol range of 20–800 μg, with an additional 2.6% being attained by increasing the dose from 400 μg to 800 μg. Another study that examined the dose-response effect on FEV₁ in healthy subjects and mild/moderate asthmatics showed a continued increase in FEV₁ over the range of 10–800 μg.

The American Thoracic Society/European Respiratory Society guidelines advise that the post-bronchodilator FEV₁ should be measured 10–15 minutes after the last of four puffs of salbutamol, but our laboratory uses an interval of only 5 minutes. This might lower the frequency with which airways reversibility is diagnosed by our laboratory. These guidelines also allow the test requestor to choose the bronchodilator (and dose). In our laboratory, it is rare for the test requestor to specify either the bronchodilator drug or dose, and none of the patients in this study had such a request.

Eleven of the 18 patients prescribed tiotropium took it within the withholding period. Whether prior use of this anticholinergic bronchodilator would affect ∆FEV₁ would depend on the relative effect of tiotropium on both baseline and post-salbutamol FEV₁ values. Published data suggest anticholinergic agents provide bronchodilatation additional to salbutamol. In a study of 20 patients with chronic obstructive pulmonary disease, 5 mg of nebulized salbutamol produced an increase in FEV₁ similar to that of ipratropium 500 μg and this effect was additive. In the recently published UPLIFT study, participants received ipratropium 80 μg followed by salbutamol 400 μg, and post-bronchodilator FEV₁ was determined 30 minutes later.

Although the participants in UPLIFT were diagnosed with chronic obstructive pulmonary disease (on the basis of age, smoking history, and PFT results), 54% experienced a bronchodilator response. The additional bronchodilator effect can serve to blur the laboratory distinction between asthma and COPD.

Some of the PFT requests in our study might have been ordered to assess whether additional benefit might be afforded by escalating therapy. In such cases, the test requestor might require the PFT to be performed without withholding β-agonists or other drugs and this would be factored into the interpretation of results. However, it is also likely that some PFTs were requested to assess patient suitability for β-blocker therapy (especially requests from cardiologists). Seventeen of the 18 subjects prescribed β-blockers in this study took them within the withholding period. If ∆FEV₁ was modest (as a result of β-blocker consumption, ie, the scenario in Figure 2A), this might have been interpreted as being safe to prescribe β-blockers. However, in reality, these patients might be at risk of bronchoconstriction. A caveat should be emphasized on the PFT report when a “negative” result (ie, ∆FEV₁ fails to reach 12% and 200 mL) is observed, and this might be as a consequence of prior drug consumption, that it does not exclude the possibility of reversible airways disease.

We chose a withholding period twice that of the published half-life for β-blockers, but this may be too conservative, especially for nonselective β-blockers and for those drugs for which the half-life might be prolonged. Longer half-lives are likely for sotalol, bisoprolol, and atenolol because they are eliminated mainly via the renal route and many patients will have impaired renal function, if only as a consequence of ageing. The very long half-life of ultra-LABAs (eg, indacaterol, half’life ≥40 hours) would require long periods of abstinence (more than three days) if an effect on ∆FEV₁ was to be minimized.

Because we did not want to affect normal laboratory practice, we were unable to repeat the PFT in the same laboratory on a proximate day when drugs likely to affect ∆FEV₁ were withheld, so we can only speculate about the actual effect on increase in FEV₁ caused by these drugs.

Disclosure

This work was presented in poster form at the Thoracic Society of Australia and New Zealand National Scientific Conference, Brisbane, Australia, March 30–April 2, 2010. Otherwise, the authors report no conflicts of interest in this work.

References


